STOCK TITAN

Gilead Sciences, Inc. - $GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: $GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gilead Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gilead Sciences's position in the market.

Rhea-AI Summary

Gilead Sciences has partnered with the White House on the Biden Cancer Moonshot initiative to enhance cancer prevention and early detection among U.S. workers. This initiative aims to improve cancer screening rates through personalized outreach, contributing to a broader effort to combat cancer. Gilead, a biopharmaceutical company known for developing innovative medicines, operates in over 35 countries and is headquartered in Foster City, California. This partnership aligns with Gilead's mission to transform and simplify care for those with life-threatening illnesses by increasing access to vital health screenings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
partnership
-
Rhea-AI Summary

Gilead Sciences (GILD) will present new research at the EASL Congress 2024 in Milan, focusing on liver diseases like PBC, HDV, HCV, HBV, and MASH/Fibrosis. Highlights include interim results from the ASSURE study on seladelpar for PBC, a Phase 2b study on Hepcludex® for HDV, and a Phase 3 study on bulevirtide monotherapy. Gilead's data aims to support WHO's goal to eliminate viral hepatitis by 2030. The company will also launch an HCV awareness program in Italy. Key findings span safety, efficacy, and long-term impacts of treatments, underscoring Gilead's commitment to addressing unmet needs in liver disease therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
conferences
-
Rhea-AI Summary

Gilead Sciences hosted its first Global Health Equity Summit on May 21, 2024, in Northampton, MA. The event brought together leaders, advocates, and changemakers to discuss strategies for improving health equity and access to care. Gilead, a biopharmaceutical company, focuses on discovering, developing, and commercializing innovative medicines for critical illnesses. The company operates in over 35 countries with its headquarters in Foster City, California.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
Rhea-AI Summary

Gilead Sciences (GILD) has announced interim results from the ASSURE study, which show that seladelpar, an investigational PPAR delta agonist, significantly improves liver disease markers and reduces itching in primary biliary cholangitis (PBC) patients. The study enrolled 174 patients, with 70% of those treated for 12 months meeting the composite endpoint, and 37% achieving ALP normalization. Seladelpar also reduced other liver injury markers. No serious adverse events were reported. This data aligns with the Phase 3 RESPONSE study, highlighting seladelpar's potential as a new therapy for PBC. The FDA has accepted a New Drug Application for seladelpar, with a decision expected in August 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Kite, a Gilead Company (Nasdaq: GILD), announced 12 abstracts from its CAR T-cell therapy portfolio at the 2024 European Hematology Association Annual Congress. Key highlights include higher manufacturing success rates and improved T-cell performance for Yescarta in second-line treatments for relapsed/refractory large B-cell lymphoma (R/R LBCL). Preliminary results from the ZUMA-24 study show promising safety and efficacy for outpatient administration of Yescarta. An oral presentation highlighted Phase 1 results and Phase 3 trial design of anitocabtagene autoleucel (anito-cel) for relapsed/refractory multiple myeloma (R/R MM). Kite's progress aims to enhance patient outcomes and CAR T-cell therapy accessibility, with additional studies on cost-effectiveness, safety, and real-world outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
-
Rhea-AI Summary

Gilead Sciences has initiated the Native Health Navigator (NHN) program, supported by their Toward Health Equity Oncology Grant. The program aims to connect Native American cancer patients to necessary medical care at CHRISTUS St. Vincent Regional Cancer Center.

Led by Olivia Sloan, a registered nurse, and Shayna Grandbois-Herrera, the program's first navigator, the NHN program assists patients with transportation, childcare, insurance, and even groceries. This initiative aims to reduce late-stage breast cancer diagnoses by providing culturally sensitive support, ultimately improving health outcomes for Native American communities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
Rhea-AI Summary

Arcellx and Kite, in partnership with Gilead Company, announced updates on their anitocabtagene autoleucel (anito-cel) multiple myeloma program. The global Phase 3 trial, iMMagine-3, will evaluate anito-cel in patients with relapsed and/or refractory multiple myeloma exposed to specific previous treatments. The technical transfer for manufacturing anito-cel is complete, and preliminary data from the iMMagine-1 trial is expected by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
none
-
Rhea-AI Summary

Kite, a Gilead Company, and Arcellx, Inc. announced operational updates on their anito-cel multiple myeloma program. They shared the iMMagine-3 trial design, manufacturing details, and plans to present data from the iMMagine-1 trial. Anito-cel is a BCMA CAR T cell therapy for relapsed/refractory multiple myeloma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
none
-
Rhea-AI Summary

Gilead's FOCUS Program, launched in 2010, has been instrumental in early HIV detection and linkage to care. By partnering with state and local officials, healthcare providers, and organizations, the program has significantly reduced late-stage HIV diagnoses in underserved populations across the United States.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
Rhea-AI Summary

Gilead's partnership with the government of Mauritius has helped in the elimination of Hepatitis C in the country. By providing low-cost treatment and working with high-prevalence regions, the company has contributed to the success of patients like James, who is now free from the disease. The government's commitment and public-private partnerships have been instrumental in the progress towards eradicating Hepatitis C in the region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
Gilead Sciences, Inc.

Nasdaq:GILD

GILD Rankings

GILD Stock Data

79.66B
1.24B
0.09%
88.37%
1.81%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
FOSTER CITY

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.